215 related articles for article (PubMed ID: 17242698)
1. Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma.
Horie N; Murata H; Kimura S; Takeshita H; Sakabe T; Matsui T; Maekawa T; Kubo T; Fushiki S
Br J Cancer; 2007 Jan; 96(2):255-61. PubMed ID: 17242698
[TBL] [Abstract][Full Text] [Related]
2. Combined effects of bisphosphonate and radiation on osteosarcoma cells.
Ryu K; Murata H; Koto K; Horie N; Matsui T; Nishigaki Y; Sakabe T; Takeshita H; Itoi M; Kimura S; Ashihara E; Maekawa T; Fushiki S; Kubo T
Anticancer Res; 2010 Jul; 30(7):2713-20. PubMed ID: 20683003
[TBL] [Abstract][Full Text] [Related]
3. Anticancer effects of zoledronic acid against human osteosarcoma cells.
Kubista B; Trieb K; Sevelda F; Toma C; Arrich F; Heffeter P; Elbling L; Sutterlüty H; Scotlandi K; Kotz R; Micksche M; Berger W
J Orthop Res; 2006 Jun; 24(6):1145-52. PubMed ID: 16602111
[TBL] [Abstract][Full Text] [Related]
4. Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents.
Koto K; Murata H; Kimura S; Horie N; Matsui T; Nishigaki Y; Ryu K; Sakabe T; Itoi M; Ashihara E; Maekawa T; Fushiki S; Kubo T
Oncol Rep; 2010 Jul; 24(1):233-9. PubMed ID: 20514467
[TBL] [Abstract][Full Text] [Related]
5. A third-generation bisphosphonate, minodronic acid (YM529), augments the interferon alpha/beta-mediated inhibition of renal cell cancer cell growth both in vitro and in vivo.
Yuasa T; Nogawa M; Kimura S; Yokota A; Sato K; Segawa H; Kuroda J; Maekawa T
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):853-9. PubMed ID: 15701876
[TBL] [Abstract][Full Text] [Related]
6. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice.
Ory B; Heymann MF; Kamijo A; Gouin F; Heymann D; Redini F
Cancer; 2005 Dec; 104(11):2522-9. PubMed ID: 16270320
[TBL] [Abstract][Full Text] [Related]
7. Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines.
Kimura S; Kuroda J; Segawa H; Sato K; Nogawa M; Yuasa T; Ottmann OG; Maekawa T
Int J Hematol; 2004 Jan; 79(1):37-43. PubMed ID: 14979476
[TBL] [Abstract][Full Text] [Related]
8. Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis.
Evdokiou A; Labrinidis A; Bouralexis S; Hay S; Findlay DM
Bone; 2003 Aug; 33(2):216-28. PubMed ID: 14499355
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines.
Matsumoto S; Kimura S; Segawa H; Kuroda J; Yuasa T; Sato K; Nogawa M; Tanaka F; Maekawa T; Wada H
Lung Cancer; 2005 Jan; 47(1):31-9. PubMed ID: 15603852
[TBL] [Abstract][Full Text] [Related]
10. The third-generation bisphosphonates inhibit proliferation of murine osteosarcoma cells with induction of apoptosis.
Horie N; Murata H; Nishigaki Y; Matsui T; Segawa H; Nogawa M; Yuasa T; Kimura S; Maekawa T; Fushiki S; Kubo T
Cancer Lett; 2006 Jul; 238(1):111-8. PubMed ID: 16112430
[TBL] [Abstract][Full Text] [Related]
11. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers.
Li YY; Chang JW; Chou WC; Liaw CC; Wang HM; Huang JS; Wang CH; Yeh KY
Lung Cancer; 2008 Feb; 59(2):180-91. PubMed ID: 17900752
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of the third-generation bisphosphonate risedronate alone and in combination with anticancer drugs against osteosarcoma cell lines.
Murayama T; Kawasoe Y; Yamashita Y; Ueno Y; Minami S; Yokouchi M; Komiya S
Anticancer Res; 2008; 28(4B):2147-54. PubMed ID: 18751388
[TBL] [Abstract][Full Text] [Related]
13. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
Lu S; Zhang J; Zhou Z; Liao ML; He WZ; Zhou XY; Li ZM; Xiang JQ; Wang JJ; Chen HQ
Oncol Rep; 2008 Sep; 20(3):581-7. PubMed ID: 18695909
[TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid, a third-generation bisphosphonate, inhibits cellular growth and induces apoptosis in oral carcinoma cell lines.
Tamura T; Shomori K; Nakabayashi M; Fujii N; Ryoke K; Ito H
Oncol Rep; 2011 Apr; 25(4):1139-43. PubMed ID: 21249320
[TBL] [Abstract][Full Text] [Related]
15. Impact of oncopediatric dosing regimen of zoledronic acid on bone growth: preclinical studies and case report of an osteosarcoma pediatric patient.
Battaglia S; Dumoucel S; Chesneau J; Heymann MF; Picarda G; Gouin F; Corradini N; Heymann D; Redini F
J Bone Miner Res; 2011 Oct; 26(10):2439-51. PubMed ID: 21713986
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer cell lines.
Koshimune R; Aoe M; Toyooka S; Hara F; Ouchida M; Tokumo M; Sano Y; Date H; Shimizu N
BMC Cancer; 2007 Jan; 7():8. PubMed ID: 17222343
[TBL] [Abstract][Full Text] [Related]
17. Increased anti-tumour effects of doxorubicin and zoledronic acid in prostate cancer cells in vitro: supporting the benefits of combination therapy.
Clyburn RD; Reid P; Evans CA; Lefley DV; Holen I
Cancer Chemother Pharmacol; 2010 Apr; 65(5):969-78. PubMed ID: 19730863
[TBL] [Abstract][Full Text] [Related]
18. Combined therapy with a new bisphosphonate, minodronate (YM529), and chemotherapy for multiple organ metastases of small cell lung cancer cells in severe combined immunodeficient mice.
Yano S; Zhang H; Hanibuchi M; Miki T; Goto H; Uehara H; Sone S
Clin Cancer Res; 2003 Nov; 9(14):5380-5. PubMed ID: 14614023
[TBL] [Abstract][Full Text] [Related]
19. Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status.
Ory B; Blanchard F; Battaglia S; Gouin F; Rédini F; Heymann D
Mol Pharmacol; 2007 Jan; 71(1):333-43. PubMed ID: 17050806
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells.
Kubo T; Shimose S; Matsuo T; Tanaka K; Yasunaga Y; Sakai A; Ochi M
J Orthop Res; 2006 Jun; 24(6):1138-44. PubMed ID: 16705696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]